Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cleveland, Ohio, that specializes in developing innovative therapies for metabolic diseases, particularly diabetes. The company focuses on hepatocyte-directed vesicle (HDV) technology, which enhances the delivery of insulin directly to liver cells (hepatocytes). This targeted approach aims to improve the efficacy and safety of insulin treatments by mimicking the liver's natural role in glucose metabolism, thus addressing a critical challenge in diabetes management where conventional insulin therapies often fail to adequately target the liver.

Overall, Diasome Pharmaceuticals is positioned as a pioneer in hepatocyte-targeted drug delivery systems, with a mission to enhance treatment outcomes for patients with metabolic diseases.

Join Us on This Journey

As part of our team, you’ll be at the forefront of groundbreaking research and development. Your contributions will play a vital role in shaping the future of diabetes care. We encourage innovation, collaboration, and a passion for excellence. Together, we will push boundaries and challenge the status quo.